Cargando…
A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is an immune-regulatory disorder characterized by excessive production of inflammatory cytokines. The treatment recommendations of the HLH- 1994 and HLH-2004 protocols have long been used in HLH therapy, but some patients still do not respond well to or have...
Autores principales: | Zhang, Qing, Wei, Ang, Ma, Hong-Hao, Zhang, Li, Lian, Hong-Yun, Wang, Dong, Zhao, Yun-Ze, Cui, Lei, Li, Wei-Jing, Yang, Ying, Wang, Tian-You, Li, Zhi-Gang, Zhang, Rui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252948/ https://www.ncbi.nlm.nih.gov/pubmed/32732367 http://dx.doi.org/10.3324/haematol.2020.253781 |
Ejemplares similares
-
Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023) -
Central Nervous System Involvement in 179 Chinese Children with Hemophagocytic Lymphohistiocytosis
por: Zhao, Yun-Ze, et al.
Publicado: (2018) -
Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis
por: Chi, Ying, et al.
Publicado: (2021) -
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021) -
Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report
por: Wang, Lina, et al.
Publicado: (2023)